Biogen announced that its experimental gene therapy for a genetic retinal disease that leads to progressive vision loss did not meet the main goal of a mid-to-late stage study.
The treatment, BIIB112, did not show significant improvement in retinal sensitivity in patients with X-linked retinitis pigmentosa, a rare eye condition that has no approved treatments.
The experimental treatment was one of the lead candidates acquired during's Biogen’s $800 million Nightstar Therapeutics buyout in 2019.
While the Phase 2/3 XIRIUS study did not meet its primary endpoint, data indicated positive trends in improving visual acuity under low light conditions and Biogen is analyzing the complete data from the study to figure out next steps.
Read the press release